Bavarian Nordic (BATS-CHIXE:BAVAC) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BAVAC Overzicht aandelen

Bavarian Nordic A/S ontwikkelt, produceert en verkoopt levensreddende vaccins.

BAVAC fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	1/6
Prestaties in het verleden	1/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 79.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 9.69% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Winstmarges (11.6%) zijn lager dan vorig jaar (19.5%)

Grote eenmalige posten die de financiële resultaten beïnvloeden

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Bavarian Nordic A/S Concurrenten

Genus

LSE:GNS

UK£1.4b

Bioventix

AIM:BVXP

UK£193.1m

PeptiDream

TSE:4587

JP¥382.4b

Ergomed

AIM:ERGO

UK£701.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bavarian Nordic
Historische aandelenkoersen
Huidige aandelenkoers	DKK 212.90
52 Week Hoogtepunt	DKK 274.05
52 Week Laag	DKK 154.48
Bèta	1.54
11 maand verandering	-14.91%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-31.54%
5 jaar verandering	32.15%
Verandering sinds IPO	228.80%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BAVAC	GB Biotechs	GB Markt
7D	-7.2%	1.2%	1.2%
1Y	n/a	-13.6%	11.6%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe BAVAC presteerde ten opzichte van de UK Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe BAVAC presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is BAVAC's price volatile compared to industry and market?
BAVAC volatility
BAVAC Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: De aandelenkoers van BAVAC is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van BAVAC in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1992	1,381	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S ontwikkelt, produceert en verkoopt levensreddende vaccins. Het bedrijf biedt niet-replicerende pokken- en apenpokkenvaccins onder de namen IMVAMUNE, IMVANEX en JYNNEOS; rabiësvaccin voor menselijk gebruik onder de naam Rabipur/RabAvert; tekenencefalitisvaccin onder de naam Encepur; en ebolavaccin onder de naam MVABEA. Het ontwikkelt ook MVA-BN voor de behandeling van pokken; MVA-BN RSV, dat zich in Fase III van de klinische testen bevindt voor de behandeling van respiratoir syncytieel virus; ABNCoV2 dat Fase III van de klinische testen voor de behandeling van SARS-CoV-2 heeft afgerond.

Bavarian Nordic A/S Samenvatting

Hoe verhouden de winst en inkomsten van Bavarian Nordic zich tot de beurswaarde?
BAVAC fundamentele statistieken
Marktkapitalisatie	DKK 17.05b
Inkomsten(TTM)	DKK 707.42m
Inkomsten(TTM)	DKK 6.08b

24.1x

Koers/Winstverhouding

2.8x

P/S-verhouding

Is BAVAC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BAVAC resultatenrekening (TTM)
Inkomsten	DKK 6.08b
Kosten van inkomsten	DKK 2.06b
Brutowinst	DKK 4.02b
Overige uitgaven	DKK 3.31b
Inkomsten	DKK 707.42m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 15, 2024

Winst per aandeel (EPS)	9.01
Brutomarge	66.08%
Nettowinstmarge	11.63%
Schuld/Eigen Vermogen Verhouding	0.2%

Hoe presteerde BAVAC op de lange termijn?

Bekijk historische prestaties en vergelijking

BAVAC Overzicht aandelen

Beloningen

Risicoanalyse

Bavarian Nordic A/S Concurrenten

LSE:GNS

UK£1.4b

AIM:BVXP

UK£193.1m

TSE:4587

JP¥382.4b

AIM:ERGO

UK£701.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Recent updates

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Less than half of directors are independent

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Less than half of directors are independent

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Less than half of directors are independent

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate